Current Systemic Lupus Erythematosis Studies
- AstraZeneca TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway) study
The TULIP study evaluates the effectiveness and safety of anifrolumab versus placebo in patients with moderately to severely active, autoantibody-positive SLE, while receiving standard of care treatment. Anifrolumab is a monoclonal antibody directed against type I interferon receptor that is administered IV ever 4 weeks. The program will assess the effect of anifrolumab in reducing disease activity (as measured by the SRI), decreasing use of OCS, improving skin manifestations (as measured by CLASI) and reducing flares.
This is currently open to new patients.
Read more about the anifrolumab at:
- Resolve Phase 1 Trial - evaluating the effect of depleting RNA immune complexes in SLE
Results of a Phase 0 proof of concept study conducted at WMR have lead to the launch of a phase 1 study evaluating RNA immune complexes in SLE pathogenesis. RSLV-132 is designed to eliminate RNA complexes that lead to chronic activation of nucleic acid sensing toll like receptors (e.g TLR7 and TLR8) and subsequent activation of the interferon inflammatory cascade. The study will provide information about safety and impact on SLE biomarkers.
Enrollment is now completed.
Want to learn more?
We have only shared a brief overview of our current research projects. If you are interested in learning more about participation, please contact our research coordinator via email using the form below. She would be happy to provide further information on specific studies via email and follow up with you on the phone to answer your questions about the details of participation. You may also reach her by calling 616.459.8088.